News
Oral Anticoagulants Compared for Gastrointestinal Safety
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
Your search for dabigatran returned 116 results
Case Studies
Drug Interaction Leads to Undetectable Levels of Oral Anticoagulant in Patient
A new report highlights the potential risk in concomitant use of the anticoagulant dabigatran, and phenytoin, a P-glycoprotein (P-gp) inducer used to treat seizure disorders.
News
Stroke, Major Bleed Risk Compared Among Novel Oral Anticoagulants
The study analyzed data from NVAF patients newly initiating treatment with dabigatran, rivaroxaban or apixaban.
News
GI Bleeding Up for New Users of Rivaroxaban
Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation
News
Dabigatran Does Not Beat Aspirin for Preventing Recurrent Stroke
Efficacy similar to aspirin for preventing recurrent stroke after embolic stroke of undetermined source
Drug News
Study: Dabigatran vs. Warfarin for Nonvalvular A-Fib
Linked to lower risk of intracranial bleeding, but higher risk of gastrointestinal bleeding
Drugs in the Pipeline
Antidote for Pradaxa Demonstrates Efficacy in Study
Boehringer Ingelheim announced results demonstrating that its investigational fully humanized antibody fragment (Fab) rapidly reversed the anticoagulation effect of dabigatran in healthy male volunteers.
American College of Cardiology 2013
Dabigatran Safe and Effective Post-Atrial Fibrillation Ablation
At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, leading cardiologists presented that the use of dabigatran following ablation for atrial fibrillation resulted in no major post-procedural complications.
News
Extended Dabigatran Effective for Venous Thromboembolism
For patients with venous thromboembolism, extended treatment with dabigatran is noninferior to warfarin.
Trial Tracker
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Pollack, CV et al. "Idarucizumab for Dabigatran Reversal — Full Cohort Analysis." DOI: 10.1056/NEJMoa1707278
